Total submissions: 38
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Courtagen Diagnostics Laboratory, |
RCV000014451 | SCV000236513 | pathogenic | Progressive sclerosing poliodystrophy | 2014-06-12 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000188580 | SCV000242202 | pathogenic | not provided | 2020-02-27 | criteria provided, single submitter | clinical testing | Accounts for approximately 10% of disease-causing alleles and has been identified in patients with autosomal recessive progressive external ophthalmoplegia (arPEO), Alpers syndrome, Leigh syndrome, SANDO, and other autosomal recessive POLG-related disorders causing epilepsy, ataxia, neuropathy, hepatopathy, and/or myopathy (Tang et al., 2011; Human DNA Polymerase Gamma Mutation Database); Published functional studies demonstrate a damaging effect, resulting in significantly impaired polymerase activity and DNA binding ability (Kasiviswanathan et al., 2009); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 27538665, 28130605, 31302675, 22616202, 21670405, 22189570, 22342071, 23448099, 12872260, 18500570, 24272679, 20513108, 20818383, 22006280, 25585994, 26692522, 27538604, 12210792, 17980715, 19478085, 27065468, 28139822, 28154168, 21880868, 18991199, 19766516, 28471437, 29655203, 30167885, 30423451, 30552426, 31996268, 33300680) |
Eurofins Ntd Llc |
RCV000188580 | SCV000331837 | pathogenic | not provided | 2016-08-02 | criteria provided, single submitter | clinical testing | |
Illumina Laboratory Services, |
RCV000363602 | SCV000394274 | pathogenic | POLG-Related Spectrum Disorders | 2017-08-28 | criteria provided, single submitter | clinical testing | The POLG c.2542G>A (p.Gly848Ser) missense variant is well-documented as one of the three most common pathogenic disease-causing variants found in patients with POLG-related disorders (Cohen et al. 2014). Haplotype analysis suggests it is most likely derived from a single ancient ancestor of European origin (Hakonen et al. 2007). The p.Gly848Ser variant has been reported in association with varied autosomal recessive phenotypes, but not in association with autosomal dominant POLG-related disorders. Across a selection of the available literature, the p.Gly848Ser variant is reported in a homozygous state in one individual with seizures who died suddenly at age five, and in a compound heterozygous state in three individuals with autosomal recessive progressive external ophthalmoplegia, two individuals with sensory ataxia neuropathy dysarthria and ophthalmoplegia, two individuals with Alpers syndrome and one individual with intractable epilepsy (Lamantea et al. 2002; Weiss et al. 2010; Milone et al. 2011; Gáti et al. 2011; Tang et al. 2011; Lax et al. 2012; Scalais et al. 2012; Uusimaa et al. 2013; Simon et al. 2014). It was also identified in one individual with progressive external ophthalmoplegia in a double heterozygous state along with a missense variant in the C10orf2 gene (Van Goethem et al. 2003). The p.Gly848Ser variant has also been identified in three unaffected heterozygous individuals (Lamantea et al. 2002). Segregation analysis in multiple families showed the p.Gly848Ser variant segregated with POLG-related disorders. The variant is absent from 200 control individuals and from 180 control chromosomes (Lamantea et al. 2002; Van Goethem et al. 2003; Tang et al. 2011) and is reported at a frequency of 0.00034 in the European (non-Finnish) population of the Genome Aggregation Database. Lamantea et al. (2002) note that the Gly848 residue is highly conserved, and functional studies by Kasiviswanathan et al. (2009) indicate that the p.Gly848Ser variant significantly impairs POLG activity and DNA binding affinity. Based on the collective evidence, the p.Gly848Ser variant is classified as pathogenic for POLG-related spectrum disorders. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population. |
Center for Pediatric Genomic Medicine, |
RCV000188580 | SCV000511422 | pathogenic | not provided | 2017-01-05 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000014451 | SCV000543865 | pathogenic | Progressive sclerosing poliodystrophy | 2024-01-29 | criteria provided, single submitter | clinical testing | This sequence change replaces glycine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 848 of the POLG protein (p.Gly848Ser). This variant is present in population databases (rs113994098, gnomAD 0.03%). This missense change has been observed in individuals with autosomal recessive POLG-related conditions (PMID: 12872260, 17426723, 18500570, 21670405, 21880868, 22006280, 22189570, 22342071, 22616202). ClinVar contains an entry for this variant (Variation ID: 13502). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt POLG protein function with a positive predictive value of 95%. Experimental studies have shown that this missense change affects POLG function (PMID: 17980715, 19478085). For these reasons, this variant has been classified as Pathogenic. |
Fulgent Genetics, |
RCV000515163 | SCV000611298 | pathogenic | Progressive sclerosing poliodystrophy; Mitochondrial DNA depletion syndrome 1; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 1; Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis; Mitochondrial DNA depletion syndrome 4b | 2022-03-12 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics | RCV000188580 | SCV000614716 | pathogenic | not provided | 2021-04-30 | criteria provided, single submitter | clinical testing | The frequency of this variant in the general population is consistent with pathogenicity (http://gnomad.broadinstitute.org). This variant segregates with disease in multiple families. Assessment of experimental evidence suggests this variant results in abnormal protein function. Experiments demonstrate a loss of >99% of polymerase activity and 5-fold reduction in DNA binding affinity (PMID: 19478085, 21228000). In multiple individuals, this variant has been seen with a single recessive pathogenic variant in the same gene, suggesting this variant may also be pathogenic. Computational tools predict that this variant is damaging. |
SIB Swiss Institute of Bioinformatics | RCV000014451 | SCV000803530 | pathogenic | Progressive sclerosing poliodystrophy | 2018-05-31 | criteria provided, single submitter | curation | This variant is interpreted as a Pathogenic, for Mitochondrial DNA depletion syndrome 4A (Alpers type), in Autosomal Recessive manner. The following ACMG Tag(s) were applied: PP3 => Multiple lines of computational evidence support a deleterious effect on the gene or gene product. PM2 => Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes Project, or Exome Aggregation Consortium. PS4-Moderate => Common mutation frequently observed in multiple unrelated patients. (PMID:17426723,21880868). PM3 => For recessive disorders, detected in trans with a pathogenic variant (PMID:19478085). PS3 => Well-established functional studies show a deleterious effect (PMID:19478085). |
Geisinger Autism and Developmental Medicine Institute, |
RCV000678386 | SCV000804455 | pathogenic | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1 | 2017-09-07 | criteria provided, single submitter | provider interpretation | This 7 year old female with autism spectrum disorder was found to carry a paternally inherited missense variant in the POLG gene. Neither she nor her father have any of the features of autosomal dominant POLG-Related Disorder, but it is possible that features have not yet emerged. Metabolic testing has thus far been normal for the patient. The p.G848S variant is a commonly reported pathogenic variant in the POLG gene, representing approximately 10% of disease-causing variants in this gene (Tang et al., 2011). The p.G848S variant was initially identified in a patient with autosomal recessive progressive external ophthalmoplegia (arPEO) and has subsequently been identified in individuals with Alpers syndrome, Leigh syndrome, SANDO, and other POLG-related disorders causing epilepsy, ataxia, neuropathy, hepatopathy, and/or myopathy (Lamantea et al., 2002). This variant alters a highly conserved position in the polymerase domain of POLG, and functional studies indicate that it significantly impairs the enzyme's polymerase activity and DNA binding ability (Kasiviswanathan et al., 2009). |
Ambry Genetics | RCV002313707 | SCV000848835 | pathogenic | Inborn genetic diseases | 2017-01-27 | criteria provided, single submitter | clinical testing | The p.G848S pathogenic mutation (also known as c.2542G>A), located in coding exon 15 of the POLG gene, results from a G to A substitution at nucleotide position 2542. The glycine at codon 848 is replaced by serine, an amino acid with similar properties. This mutation was first described in an individual with progressive external ophthalmoplegia (PEO), cytochrome c oxidase-neg ragged red fibers, and multiple mtDNA deletions in skeletal muscle who was compound heterozygous for another pathogenic POLG alteration (Lamantea E et al. Ann. Neurol., 2002 Aug;52:211-9). This mutation is located in the catalytic polymerase domain and is one of the most common POLG mutations, accounting for approximately 10% of mutant alleles in one large cohort of over 2000 patients with phenotypes suspicious for POLG deficiencies, including autosomal recessive PEO (arPEO), Alpers syndrome, and seizures (Tang S et al. J Med Genet. 2011 Oct;48(10):669-81). Based on the available evidence, p.G848S is classified as a pathogenic mutation. |
Wong Mito Lab, |
RCV000014451 | SCV000887116 | pathogenic | Progressive sclerosing poliodystrophy | 2018-10-01 | criteria provided, single submitter | clinical testing | The NM_002693.2:c.2542G>A (NP_002684.1:p.Gly848Ser) [GRCH38: NC_000015.10:g.89321792C>T] variant in POLG gene is interpretated to be a Pathogenic based on ACMG guidelines (PMID: 25741868). This variant has been reported in PMID:12210792 ; 16177225 . This variant meets the following evidence codes reported in the ACMG-guideline. PS1:This variation causes same amino-acid change as an established pathogenic variant. PS3:Well established functional studies show a deleterious effect on POLG. PM2:This variant is absent in key population databases. PM3:Detected in trans with a pathogenic variant for Mitochondrial DNA depletion syndrome 4A (Alpers type) which is a recessive disorder. PP1:This variant is co-segregated with Mitochondrial DNA depletion syndrome 4A (Alpers type) in multiple affected family members. PP4:Patient's phenotype or family history is highly specific for POLG. Based on the evidence criteria codes applied, the variant is suggested to be Pathogenic. |
Ce |
RCV000188580 | SCV000892141 | pathogenic | not provided | 2023-07-01 | criteria provided, single submitter | clinical testing | POLG: PM3:Very Strong, PM2, PP3, PS3:Supporting |
Center for Genomics, |
RCV001027839 | SCV001190459 | pathogenic | Progressive sclerosing poliodystrophy; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 1; Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis; Mitochondrial DNA depletion syndrome 4b | 2021-03-30 | criteria provided, single submitter | clinical testing | POLG NM_002693.2 exon 16 p.Gly848Ser (c.2542G>A): This variant has been reported in the literature in the compound heterozygous or homozygous state in several individuals with autosomal recessive progressive external opthalmoplegia as well as a wide variety of additional POLG-related phenotypes (Lamantea 2002 PMID:12210792, Weiss 2010 PMID:20513108, Milone 2011 PMID:21670405, Tang 2011 PMID:21880868, Scalais 2012 PMID:22342071, Uusimaa 2013 PMID:23448099, Simon 2014 PMID:2014 PMID:24272679). Literature suggests that this variant is one of the most common pathgenic variants in the POLG gene (Hakonen, 2007 PMID:17426723, Tang 2011 PMID:21880868). This variant is present in 0.03% (40/129136) of European alleles in the Genome Aggregation Database (https://gnomad.broadinstitute.org/variant/15-89865023-C-T). Please note, disease causing variants may be present in control databases at low frequencies, reflective of the general population, carrier status, and/or variable expressivity. This variant is present in ClinVar, with several labs classifying this variant as pathogenic (Variation ID:13502). Evolutionary conservation and computational predictive tools suggest that this variant may impact the protein. In addition, functional studies indicate that this variant leads to decreased enzyme activity and reduced DNA binding affinity (Kasivishwanathan 2009 PMID:19478085). However, these studies may not accurately represent in vivo biological function. In summary, this variant is classified as pathogenic based on the data above. |
Institute of Medical Genetics and Applied Genomics, |
RCV000188580 | SCV001447477 | pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Equipe Genetique des Anomalies du Developpement, |
RCV000014451 | SCV001554491 | pathogenic | Progressive sclerosing poliodystrophy | criteria provided, single submitter | clinical testing | ||
Rady Children's Institute for Genomic Medicine, |
RCV001027839 | SCV001984826 | pathogenic | Progressive sclerosing poliodystrophy; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 1; Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis; Mitochondrial DNA depletion syndrome 4b | 2020-07-21 | criteria provided, single submitter | clinical testing | This variant has been previously reported as a compound heterozygous change in multiple patients with autosomal recessive POLG-related disorders including Alpers-Huttenlocher syndrome (AHS), sensory ataxic neuropathy, optic Atrophy, intractable epilepsy and early onset epileptic encephalopathy (PMID: 12210792, 22189570, 23448099, 30552426, 30423451, 29655203). Functional characterization indicates that the p.Gly848Ser variant, which is located in the thumb domain of the protein and affects a conserved glycine residue upstream of motif polA, results in <1% polymerase activity, and in a defect in DNA binding function (PMID: 19478085). In addition, studies in model organisms indicated that the yeast-equivalent of the p.Gly848Ser variant results in high mtDNA instability (PMID: 17980715). The p.Gly848Ser variant is present in the heterozygous state in the gnomAD population database at a frequency of 0.017% (48/282794) and thus is presumed to be rare. In silico analyses support a deleterious effect of the c.2542G>A (p.Gly848Ser) variant on protein function. Based on the available evidence, the c.2542G>A (p.Gly848Ser) variant is classified as Pathogenic. |
Institute for Clinical Genetics, |
RCV000188580 | SCV002010403 | pathogenic | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV000188580 | SCV002019466 | pathogenic | not provided | 2022-02-15 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV001847601 | SCV002105571 | pathogenic | Hereditary spastic paraplegia | 2018-11-01 | criteria provided, single submitter | clinical testing | |
DASA | RCV000363602 | SCV002107104 | pathogenic | POLG-Related Spectrum Disorders | 2022-03-05 | criteria provided, single submitter | clinical testing | Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product (PMID:19478085; 17980715) - PS3_moderate.The c.2542G>A;p.(Gly848Ser) missense variant has been observed in affected individual(s) and ClinVar contains an entry for this variant (ClinVar ID: 13502; PMID: 17426723; PMID: 21880868; PMID: 18500570; PMID: 12872260; PMID: 22616202; PMID: 22006280; PMID: 22342071; PMID: 21670405; PMID: 22189570) - PS4. The variant is located in a mutational hot spot and/or critical and well-established functional domain (DNA_pol_A) - PM1. The variant is present at low allele frequencies population databases (rs113994098 – gnomAD 0.001697%; ABraOM 0.000854 frequency - http://abraom.ib.usp.br/) - PM2_supporting. The p.(Gly848Ser) was detected in trans with a pathogenic variant (PMID:19478085) - PM3. Multiple lines of computational evidence support a deleterious effect on the gene or gene product - PP3. In summary, the currently available evidence indicates that the variant is pathogenic. |
Institute of Human Genetics, |
RCV002054437 | SCV002496144 | pathogenic | Progressive sclerosing poliodystrophy; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1; Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 1; Mitochondrial DNA depletion syndrome 4b | 2022-01-20 | criteria provided, single submitter | clinical testing | ACMG categories: PS3,PM1,PM2,PP3,PP5,BP1 |
Genetics and Molecular Pathology, |
RCV000678386 | SCV002761805 | pathogenic | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 1 | 2021-04-17 | criteria provided, single submitter | clinical testing | The POLG c.2542G>A variant is classified as Pathogenic (PS3, PS4, PP1, PP3) The POLG c.2542G>A variant is a single nucleotide change in exon 16 of the POLG gene, which is predicted to change the amino acid glycine at position 848 in the protein to serine. The variant has been reported in probands with a clinical presentation of progressive external ophthalmoplegia (PS4). Multiple cases reported in literature: 23 entries in ClinVAR ( all P/LP) This variant co-segregates with disease (PP1). PP1:This variant is co-segregated with Mitochondrial DNA depletion syndrome 4A (Alpers type) in multiple affected family members. PP4:Patient's phenotype or family history is highly specific for POLG. Well-established functional studies show a deleterious effect of this variant (PS3). Lamantea et al. (2002) note that the Gly848 residue is highly conserved, and functional studies by Kasiviswanathan et al. (2009) indicate that the p.Gly848Ser variant significantly impairs POLG activity and DNA binding affinity. Computational predictions support a deleterious effect on the gene or gene product (PP3). The variant has been reported in dbSNP (rs113994098) and has been reported as Pathogenic/Likely pathogenic by other diagnostic laboratories (ClinVar Variation ID: 13502). |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003230362 | SCV003929297 | pathogenic | Mitochondrial DNA depletion syndrome | 2023-04-11 | criteria provided, single submitter | clinical testing | Variant summary: POLG c.2542G>A (p.Gly848Ser) results in a non-conservative amino acid change located in the DNA polymerase gamma, palm domain (IPR047580) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.00015 in 251408 control chromosomes. This frequency is not significantly higher than estimated for a pathogenic variant in POLG causing Mitochondrial DNA Depletion Syndrome (0.00015 vs 0.0035), allowing no conclusion about variant significance. c.2542G>A has been reported in the literature in compound heterozygous and homozygous individuals affected with Mitochondrial DNA Depletion Syndrome - POLG Related (e.g., Tang_2011). These data indicate that the variant is very likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function, finding that the variant results in <1% of normal polymerase activity (e.g., Kasiviswanathan_2009). Multiple ClinVar submitters (evaluation after 2014) have cited the variant, and all laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Daryl Scott Lab, |
RCV003231103 | SCV004102724 | pathogenic | POLG-related disorder | 2023-11-10 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV003231103 | SCV004120250 | pathogenic | POLG-related disorder | 2022-12-21 | criteria provided, single submitter | clinical testing | The POLG c.2542G>A variant is predicted to result in the amino acid substitution p.Gly848Ser. This variant has been reported to be causative for a variety of autosomal recessive POLG-associated disorders, such as sensory ataxia neuropathy with dysarthria/dysphagia and ophthalmoplegia (SANDO), Alpers’ Syndrome, Leigh-like syndrome, intractable epilepsy, and progressive external ophthalmoplegia (PEO) (Gáti et al. 2011. PubMed ID: 22616202; Simon et al. 2014. PubMed ID : 24272679; Uusimaa et al. 2013. PubMed ID : 23448099; Lamantea et al. 2002. PubMed ID: 12210792). The p.Gly848Ser variant protein retained less than 1% of catalytic activity compared to the wild type enzyme (Kasiviswanathan et al. 2009. PubMed ID: 19478085). This variant is reported in 0.0085% of alleles in individuals of African descent in gnomAD (http://gnomad.broadinstitute.org/variant/15-89865023-C-T). We classify this variant as pathogenic. |
Baylor Genetics | RCV000014451 | SCV004205836 | pathogenic | Progressive sclerosing poliodystrophy | 2023-10-30 | criteria provided, single submitter | clinical testing | |
Department of Genetics, |
RCV000014451 | SCV004543837 | pathogenic | Progressive sclerosing poliodystrophy | 2023-05-26 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000014449 | SCV000034699 | pathogenic | Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 1 | 2009-03-24 | no assertion criteria provided | literature only | |
OMIM | RCV000014450 | SCV000034700 | pathogenic | Progressive external ophthalmoplegia with mitochondrial DNA deletions, digenic | 2009-03-24 | no assertion criteria provided | literature only | |
OMIM | RCV000014451 | SCV000034701 | pathogenic | Progressive sclerosing poliodystrophy | 2009-03-24 | no assertion criteria provided | literature only | |
OMIM | RCV000014452 | SCV000034702 | pathogenic | Mitochondrial DNA depletion syndrome 4b | 2009-03-24 | no assertion criteria provided | literature only | |
Gene |
RCV002272018 | SCV000040910 | not provided | Mitochondrial disease | no assertion provided | literature only | ||
Genome |
RCV003231103 | SCV000607021 | not provided | POLG-related disorder | no assertion provided | phenotyping only | Variant reported in multiple GenomeConnect participants by GeneDx. Variant interpreted as Pathogenic and reported, most recently, on 2016-10-31. GenomeConnect assertions are reported exactly as they appear on the patient-provided report from the testing laboratory. GenomeConnect staff make no attempt to reinterpret the clinical significance of the variant. | |
Diagnostic Laboratory, |
RCV000188580 | SCV001740770 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000188580 | SCV001807715 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000188580 | SCV001955119 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000188580 | SCV001965694 | pathogenic | not provided | no assertion criteria provided | clinical testing |